Investors
Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic diseases.
Nasdaq: AGIO
    
Events & Presentations
Upcoming Events
There are currently no events scheduled.
Past Events
Q1 2017 Agios Pharmaceuticals Inc Earnings Conference Call
Thursday, May 4, 2017 8:00 a.m. ET
Supporting Materials
Download Event Supporting Material First Quarter 2017 Financial Results Presentation

Agios Pharmaceuticals Inc at 16th Annual Needham Healthcare Conference
Tuesday, April 4, 2017 9:20 a.m. ET
Supporting Materials
Download Event Supporting Material 16th Annual Needham Healthcare Conference Presentation

Agios Pharmaceuticals Inc at Cowen and Company 37th Annual Health Care Conference
Monday, March 6, 2017 2:00 p.m. ET

Q4 2016 Agios Pharmaceuticals Inc Earnings Conference Call
Thursday, February 16, 2017 8:00 a.m. ET
Supporting Materials
Download Event Supporting Material Fourth Quarter 2016 Financial Results Presentation

Agios Pharmaceuticals Inc at 35th Annual J.P. Morgan Healthcare Conference
Monday, January 9, 2017 10:00 a.m. PT
Supporting Materials
Download Event Supporting Material J.P. Morgan Healthcare Conference Presentation

Agios Conference Call
Thursday, December 15, 2016 5:00 p.m. ET

Agios Pharmaceuticals Inc ASH 2016 Webcast
Sunday, December 4, 2016 8:00 p.m. PT
Supporting Materials
Download Event Supporting Material Agios Data Update at ASH

Q3 2016 Agios Pharmaceuticals Inc Earnings Conference Call
Thursday, November 3, 2016 8:00 a.m. ET
Supporting Materials
Download Event Supporting Material Third Quarter 2016 Financial Results Presentation

Q2 2016 Agios Pharmaceuticals Inc Earnings Conference Call
Thursday, August 4, 2016 8:30 a.m. ET
Supporting Materials
Download Event Supporting Material Second Quarter 2016 Financial Results Presentation

Presentations
DateTitle
06/24/17
Download Documentation Enasidenib in mutant-IDH2 Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): Results of a Phase 1/2 study
06/24/17
Download Documentation Effects of AG-348, a pyruvate kinase activator, in patients with pyruvate kinase deficiency: Updated results from the DRIVE PK study
06/06/17
Download Documentation Enasidenib in mutant IDH2 R/R AML: results of Phase 1 dose escalation and expansion study
06/05/17
Download Documentation Differentiation Syndrome associated with enasidenib, a selective inhibitor of mutant IDH2
06/03/17
Download Documentation Phase 1 study of AG-120, an IDH1 mutant enzyme inhibitor: results from the cholangiocarcinoma dose escalation and expansion cohorts
06/03/17
Download Documentation Pharmacokinetic/pharmacodynamic (PK/PD) profile of AG-120 in patients with IDH1-mutant cholangiocarcinoma from a phase 1 study of advanced solid tumors
06/03/17
Download Documentation ClarIDHy: a phase 3, multicenter, randomized, double-blind study of AG-120 vs placebo in patients with an advanced cholangiocarcinoma with an IDH1 mutation
12/05/16
Download Documentation Determination of IDH1 Mutational Burden and Clearance via Next-Generation Sequencing in Patients With IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Inhibitor of Mutant IDH1
Get help downloading or viewing the above file types